Dianthus Therapeutics (DNTH) to Release Quarterly Earnings on Thursday

Dianthus Therapeutics (NASDAQ:DNTH) is anticipated to announce its earnings results before the market opens on Thursday, March 20th. Analysts expect the company to announce earnings of ($0.69) per share and revenue of $0.86 million for the quarter.

Dianthus Therapeutics (NASDAQ:DNTH) last issued its quarterly earnings results on Tuesday, March 11th. The company reported ($0.81) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.85) by $0.04. The company had revenue of $1.33 million for the quarter, compared to analyst estimates of $1.40 million. Dianthus Therapeutics had a negative net margin of 1,250.32% and a negative return on equity of 21.68%. On average, analysts expect Dianthus Therapeutics to post $-3 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Dianthus Therapeutics Stock Down 6.3 %

Dianthus Therapeutics stock opened at $21.90 on Thursday. Dianthus Therapeutics has a 52-week low of $18.13 and a 52-week high of $33.77. The firm has a market cap of $648.17 million, a PE ratio of -8.76 and a beta of 1.82. The company’s 50 day moving average is $22.65 and its two-hundred day moving average is $24.94.

Analysts Set New Price Targets

Several equities analysts have commented on the stock. TD Cowen started coverage on shares of Dianthus Therapeutics in a research note on Friday, December 20th. They issued a “buy” rating on the stock. Guggenheim reaffirmed a “buy” rating and issued a $84.00 target price on shares of Dianthus Therapeutics in a research report on Wednesday. Wedbush reissued an “outperform” rating and issued a $36.00 price target on shares of Dianthus Therapeutics in a research report on Wednesday. Raymond James upgraded shares of Dianthus Therapeutics to a “moderate buy” rating in a research note on Thursday, December 12th. Finally, HC Wainwright reiterated a “buy” rating and set a $40.00 target price on shares of Dianthus Therapeutics in a research report on Wednesday. Eight investment analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat, Dianthus Therapeutics currently has a consensus rating of “Buy” and an average price target of $52.14.

Dianthus Therapeutics Company Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.